Previous 10 | Next 10 |
Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.02M (-87.5% Y/Y) beats by $0.01M . As of June 30, 2022, Checkpoint’s cash and cash equivalents totaled $30.9 million, compared to $41.5 million at March 31, ...
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July 2022 Biologics license application (“BLA”) submission for...
Checkpoint Therapeutics (NASDAQ:CKPT) said that interim results from a registrational-enabling trial showed efficacy for cosibelimab for locally advanced cutaneous squamous cell carcinoma (cSCC). As of March 2022, the the objective response rate (ORR) in 31 patients was 54.8%. Based on t...
Redbox Entertainment (RDBXW) +70%. Sidus Space (SIDU) +45%. Redbox Entertainment (RDBX) +18%. Seres Therapeutics (MCRB) +13%. Checkpoint Therapeutics (CKPT) +12%. Mobiquity Technologies (MOBQ) +9%. Humanigen (HGEN) +6% as it enters pact with PCI Pharma Services in UK for lenzilumab....
Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2 nd indication for cosibelimab Previously met primary endpoint in patients with metastatic cSCC; BLA submission on track for later this year Company to continue discussions ...
WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of data from its pivotal trial of cosibelimab in metastatic cutaneous squamous cell car...
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a company overvi...
The shares of clinical-stage biotech Checkpoint Therapeutics (NASDAQ:CKPT) are trading sharply higher on Friday as H.C. Wainwright welcomes the Pediatric Investigation Plan (PIP) product-specific waivers granted for the company's cancer candidate cosibelimab in the EU and U.K. On Friday, Chec...
WALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has received Pediatric Investigation Plan (PIP) product-specific waivers from the European Medici...
Checkpoint Therapeutics press release (NASDAQ:CKPT): Q1 GAAP EPS of -$0.20. As of March 31, 2022, Checkpoint’s cash and cash equivalents totaled $41.5 million, compared to $54.7 million at December 31, 2021, a decrease of $13.2 million. For further details see: Checkpoint Therape...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...